The phase 1b/2 UPLIFT (NCT03319628) study evaluated Upifitamab rilsodotin (UpRi, XMT-1536), an ADC targeting NaPi2b, in patients with platinum-resistant ovarian cancer [123]. Here, SLC34A2 is linked to ovarian carcinoma.